Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Invion Limited

ABN

76 094 730 417

We (the entity) give ASX the following information.

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Fully paid ordinary shares

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- of Principal terms the 3 +securities (e.g. if options, exercise price and expiry date; if +securities, the partly paid amount outstanding and due dates for payment; if +convertible the securities, conversion price and dates for conversion)

Fully paid ordinary shares issued following receipt of option exercise notice and exercise price per option in relation to options on issue exercisable at \$0.0175 each on or before 18 November 2020. 10,000,000 options were exercised at a total exercise price of \$175,000.

<sup>+</sup> See chapter 19 for defined terms.

4	<ul> <li>Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?</li> <li>If the additional *securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next</li> </ul> </li> </ul>	Yes
	dividend, distribution or interest payment	
5	Issue price or consideration	\$0.0175
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Shares issued following receipt of option exercise notice and exercise price per option in relation to options on issue exercisable at \$0.0175 each on or before 18 November 2020. 10,000,000 options were exercised at a total exercise price of \$175,000.
ба	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2017
6c	Number of +securities issued	Nil

under rule 7.1

without security holder approval

<sup>+</sup> See chapter 19 for defined terms.

- 6d Number of \*securities issued with security holder approval under rule 7.1A
- 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.
- 6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 <sup>+</sup>Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	+Class
5,463,522,967	Fully paid ordinary shares

N/A

N/A

N/A

N/A

N/A

781,978,445 under LR 7.1

545,152,297 Under LR7.1A

26 April 2018

+ See chapter 19 for defined terms.

		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	19,700,000	Shareoptionsexercisableat \$0.12each on or before 9November2018(IVXAM)
		1,702,353	Shareoptionsexercisableat \$0.04each on orbefore 9November2019(IVXAQ)
		5,005,000	Share options exercisable at \$0.0175 each on or before 18 November 2020 (IVXAS)
		23,750,000	CI
			Share options exercisable at \$0.0175
			each on or before 18
			November 2020 (IVXAT)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable

# Part 2 - Pro rata issue – not applicable

11	Is security holder approval required?
12	Is the issue renounceable or non- renounceable?
13	Ratio in which the <sup>+</sup> securities will be offered
14	+Class of +securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different
10	registers (or subregisters) be aggregated for calculating
	entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee
	payable to brokers who lodge acceptances or renunciations on behalf of security holders
25	If the issue is contingent on security holders' approval, the date of the meeting
ſ	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 0	Detervishes trading will have (f)
28	Date rights trading will begin (if

<sup>+</sup> See chapter 19 for defined terms.

	applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
2	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	

## Part 3 - Quotation of securities - n/a

You need only complete this section if you are applying for quotation of securities

- 34 Type of +securities (*tick one*)
- (a) +Securities described in Part 1

#### (b) All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35

If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders

<sup>+</sup> See chapter 19 for defined terms.

36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37	A copy of any trust deed for the additional <sup>+</sup> securities		
Entitie	es that have ticked box 34(b)		
38	Number of <sup>+</sup> securities for which <sup>+</sup> quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the <sup>+</sup> securities rank equally in all respects from the <sup>+</sup> issue date with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?		
	<ul> <li>If the additional <sup>+</sup>securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another <sup>+</sup> security, clearly identify that other <sup>+</sup> security)		
		Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in clause 38)

<sup>+</sup> See chapter 19 for defined terms.

#### Quotation agreement

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those *\*securities* should not be granted *\*quotation*.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

== == == == ==

Medand

Sign here:

(Director/Company secretary)

Date: 26 April 2018

Print name:

**Melanie Farris** 

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
<i>Insert</i> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	1,237,071,273		
<ul> <li>Add the following:</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> <li>Number of partly ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	185,560,667 placement shares ratified at the AGM held 30 November 2017 33,333,333 placement shares ratified at the AGM held 30 November 2017 2,750,000,000 shares approved at the AGM held 30 November 2017 1,245,557,694 rights issue entitlement offer shares issued 15 March 2018		
"A"	5,451,522,967		

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	817,728,445
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<ul> <li>Insert number of <sup>+</sup>equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	23,750,000 unlisted share options 2,000,000 shares issued upon exercise of options 10,000,000 shares issued upon exercise of options (subject of this 3B)
"C"	35,750,000
Step 4: Subtract "C" from ["A" x "I placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	817,728,445
Note: number must be same as shown in Step 2	
Subtract "C"	35,750,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	781,978,445
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

# Part 2

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
"A"	5,451,522,967		
Note: number must be same as shown in Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
<i>Multiply</i> "A" by 0.10	545,152,297		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	0		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"E"	545,152,297		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	545,152,297	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	545,152,297	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.